New Review Highlights the Latest Developments in Pediatric Anaplastic Large Cell Lymphoma
LONDON, May 22, 2018 /PRNewswire/ --
Soumitra Tole, Laura Wheaton, Sarah Alexander, Oncology & Hematology Review. 2018;14(1):21-27 DOI: https://doi.org/10.17925/OHR.2018.14.1.21
Published recently in Oncology & Hematology Review, the peer-reviewed journal from touchONCOLOGY, Tole et al review the pathology, clinical presentation, and prognostic factors for pediatric ALCL, and discuss the therapeutic strategies for the disease. Anaplastic large cell lymphoma (ALCL) is the most common pediatric peripheral T-cell lymphoma, accounting for 10-15% of pediatric non-Hodgkin lymphoma. Patients with pediatric ALCL commonly present at an advanced stage of disease and, unlike adult ALCL, the majority of pediatric cases demonstrate overexpression of anaplastic lymphoma kinase (ALK). Despite a range of treatment strategies, event-free survival has remained stagnant at 65-75%. The role of novel targeted therapies such as ALK inhibitors and anti-CD30 antibody drug conjugates are actively being studied in both the newly diagnosed and relapse setting.
(Logo: http://mma.prnewswire.com/media/515766/Touch_Medical_Logo.jpg )
The full peer-reviewed, open-access article is available here:
https://doi.org/10.17925/OHR.2018.14.1.21
Disclosure: Soumitra Tole, Laura Wheaton, and Sarah Alexander have nothing to declare in relation to this article. No funding was received in the publication of this article.
touchONCOLOGY (a division of Touch Medical Media) publishesOncology & Hematology Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology and hematology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
"Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142".
For inquires please contact:
Nicola Cartridge - Editorial Director
editor@touchmedicalmedia.com
"Leading the Debate on the Advances in Healthcare"
SOURCE touchONCOLOGY
Share this article